Accessibility Menu
Pharmagreen Biotech logo

Pharmagreen Biotech(OTC) PHBI

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-98%
1 Year-50%
1 Month-50%
N/A
Pharmagreen Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.902026-08-14
Pharmagreen Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-50%USD 1.802026-08-06
1 month-50%USD 1.802026-07-15
3 month-71.88%USD 3.202026-05-15
Year to date-79.55%USD 4.402025-12-31
1 year-50%USD 1.802025-08-14
3 year-62.5%USD 2.402023-08-15
5 year-98.04%USD 46.002021-08-13
Since inception-99.98%USD 5,600.002018-06-05

Pharmagreen Biotech Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.33M

Net Income (TTM)

-$1.26M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 11, 2026

PHBI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pharmagreen Biotech

Pharmagreen Biotech Inc. is a biotechnology solutions provider focused on cultivating young plant stock for the medical cannabis and CBD hemp industries. Established in 2007 and based in Coquitlam, Canada, the company aims to leverage its expertise in plant cultivation to meet the growing demand in the cannabis sector.

Products and Services
  • Young plant stock cultivation for medical cannabis
  • CBD hemp plant stock production
  • Biotechnology solutions tailored for the cannabis industry
Growth Outlook
  • Increasing demand for medical cannabis and CBD products drives market potential
  • Expansion plans to enhance cultivation capabilities and product offerings
  • Strategic positioning in a rapidly growing industry with significant future growth
Financial Highlights
  • Recent quarterly revenue of 911,699, showing potential for growth
  • Trailing twelve months (TTM) revenue of 3,422,072, indicating a strong sales trajectory
  • Current ratio of 0.075 suggests a focus on improving liquidity
Pharmagreen Biotech Inc. operates in a dynamic and expanding market, with a clear focus on the cultivation of young plant stock for the medical cannabis and CBD hemp industries. The company's recent revenue figures indicate a positive trend, reflecting its potential to capitalize on the growing demand for cannabis-related products. With plans for expansion and a strategic approach to enhancing its cultivation capabilities, Pharmagreen is well-positioned to navigate the evolving landscape of the biotechnology sector. The financial metrics, including the recent quarterly revenue and TTM figures, suggest a commitment to growth, although attention to liquidity will be essential for future operations. As the market for medical cannabis continues to expand, Pharmagreen Biotech Inc. stands to benefit from its specialized focus and industry expertise.
AI Generated • Jul 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Website

www.pharmagreen.ca

Headquarters

Coquitlam, BC V3E 3A2, CA

PHBI Financials

Key Financial Metrics (TTM)

Gross Margin

-0.02%

Operating Margin

-31.60%

Net Income Margin

-29.06%

Return on Equity

21.06%

Return on Capital

N/A

Return on Assets

-153.15%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$1.03K

Operating Income

-$1.37M

EBITDA

-$1.27M

Operating Cash Flow

-$23.30K

Capital Expenditure

-$3.00

Free Cash Flow

-$23.31K

Cash & ST Invst.

$234.69K

Total Debt

$266.07K

Pharmagreen Biotech Performance Analysis

Pharmagreen Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30USD 0N/A
20232023-09-30USD 2,998N/A
20242024-09-30USD 3,41013.7%
20252025-09-30USD 2,388-30.0%
Pharmagreen Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-06-30-47.4%
Q42025-09-3075.5%
Q12025-12-31581885.0%
Q22026-03-31-73.4%
Pharmagreen Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30USD -4.34-85.9%
20232023-09-30USD -2.44-43.8%
20242024-09-30USD -3.0424.6%
20252025-09-30USD 0.62N/A
Pharmagreen Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-06-30150.0%
Q42025-09-30-700.0%
Q12025-12-31-183.3%
Q22026-03-31100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$911.70K

+143023.9%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-$65.14K

+51.5%

EBITDA

-$66.27K

+47.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$234.69K

+36917.5%

Total Debt

$266.07K

-24.6%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$266.07K

+0.6%

Return on Assets

-1.53%

N/A

Return on Invested Capital

14.55%

N/A

Free Cash Flow

-$3.24K

-404.8%

Operating Cash Flow

-$3.24K

-404.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MSTHMystic Holdings, Inc.
$0.00+0.00%
ALIDAllied Corp.
$0.00+0.00%
EXMTAnything Technologies Media, Inc.
$0.00+0.00%
CBDYTarget Group Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About PHBI

What is the current price of Pharmagreen Biotech?

Pharmagreen Biotech is trading at N/A per share.

What is the 52-week range for Pharmagreen Biotech?

Over the past 52 weeks, Pharmagreen Biotech has traded between N/A and N/A.

How much debt does Pharmagreen Biotech have?

As of the most recent reporting period, Pharmagreen Biotech reported total debt of $266.07K.

How much cash does Pharmagreen Biotech have on hand?

Pharmagreen Biotech reported $234.69K in cash and cash equivalents in its most recent financial results.

What is Pharmagreen Biotech’s dividend yield?

Pharmagreen Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services